Regeneron Pharmaceuticals, Inc.
REGN
$828.50
-$5.54-0.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.81% | -10.08% | -7.97% | 8.91% | -2.84% |
| Total Depreciation and Amortization | -8.44% | -2.92% | 14.72% | 12.33% | 11.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 126.94% | 1,055.22% | -42.58% | -462.50% | 46.85% |
| Change in Net Operating Assets | -184.86% | -71.84% | 106.83% | 1,078.09% | 74.91% |
| Cash from Operations | -28.96% | 3.23% | -7.29% | 25.36% | 223.28% |
| Capital Expenditure | -9.68% | -0.57% | -24.60% | 16.74% | -21.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 97.39% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.86% | -122.62% | -16.45% | 40.30% | -123.33% |
| Cash from Investing | 91.53% | -166.24% | -37.16% | 29.86% | -96.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.19% | 169.14% | 453.91% | -84.18% | -92.80% |
| Repurchase of Common Stock | -10.30% | 17.04% | 2.89% | 22.02% | -16.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.54% | -4.26% | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -8.54% | 26.35% | 31.30% | -13.23% | -135.98% |
| Foreign Exchange rate Adjustments | -175.00% | -250.00% | 57.14% | -150.00% | 233.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.17% | -125.35% | 27.95% | 495.10% | -58.07% |